Literature DB >> 34041611

Management of Lower Urinary Tract Symptoms after Prostate Radiation.

Pansy Uberoi1, Charlton A Smith2, Alvaro Lucioni3.   

Abstract

PURPOSE OF REVIEW: To present urologists with guidance on how to approach and manage lower urinary tract symptoms (LUTS) in patients who have undergone radiation therapy (RT) for prostate cancer. RECENT
FINDINGS: There are few studies that specifically examine treatment approaches for LUTS in patients who have undergone prostate cancer RT. LUTS after prostate RT are unique when compared to de novo LUTS. Understanding these distinctions is important for urologists' practice as well as patients' quality of life. Discussion of the risks and management of post-RT LUTS should be included in the shared decision-making process when counseling patients on various treatment options for prostate cancer. Further studies evaluating treatments for storage and voiding symptoms after RT are needed to help guide future care.

Entities:  

Keywords:  Lower urinary tract symptoms; Overactive bladder; Post-radiation; Prostate cancer; Stress incontinence

Mesh:

Year:  2021        PMID: 34041611     DOI: 10.1007/s11934-021-01048-8

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  61 in total

1.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Authors:  Sree Rodda; W James Morris; Jeremy Hamm; Graeme Duncan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-02-21       Impact factor: 7.038

3.  Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial.

Authors:  Daniel A Hamstra; Neil Mariados; John Sylvester; Dhiren Shah; Lawrence Karsh; Richard Hudes; David Beyer; Steven Kurtzman; Jeffrey Bogart; R Alex Hsi; Michael Kos; Rodney Ellis; Mark Logsdon; Shawn Zimberg; Kevin Forsythe; Hong Zhang; Edward Soffen; Patrick Francke; Constantine Mantz; Peter Rossi; Theodore DeWeese; Stephanie Daignault-Newton; Benjamin W Fischer-Valuck; Anupama Chundury; Hiram Gay; Walter Bosch; Jeff Michalski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-12-23       Impact factor: 7.038

4.  Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).

Authors:  Colleen A Lawton; Michelle DeSilvio; W Robert Lee; Leonard Gomella; David Grignon; Michael Gillin; Gerard Morton; Thomas Pisansky; Howard Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-02       Impact factor: 7.038

5.  The pathophysiology of lower urinary tract symptoms after brachytherapy for prostate cancer.

Authors:  Jerry G Blaivas; Jeffrey P Weiss; Mark Jones
Journal:  BJU Int       Date:  2006-12       Impact factor: 5.588

6.  Incontinence after Prostate Treatment: AUA/SUFU Guideline.

Authors:  Jaspreet S Sandhu; Benjamin Breyer; Craig Comiter; James A Eastham; Christopher Gomez; Daniel J Kirages; Chris Kittle; Alvaro Lucioni; Victor W Nitti; John T Stoffel; O Lenaine Westney; M Hassan Murad; Kurt McCammon
Journal:  J Urol       Date:  2019-07-08       Impact factor: 7.450

7.  National trends in management of localized prostate cancer: A population based analysis 2004-2013.

Authors:  Junchao Chen; Clara Oromendia; Joshua A Halpern; Karla V Ballman
Journal:  Prostate       Date:  2018-03-14       Impact factor: 4.104

8.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

9.  Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Authors:  W Robert Lee; James J Dignam; Mahul B Amin; Deborah W Bruner; Daniel Low; Gregory P Swanson; Amit B Shah; David P D'Souza; Jeff M Michalski; Ian S Dayes; Samantha A Seaward; William A Hall; Paul L Nguyen; Thomas M Pisansky; Sergio L Faria; Yuhchyau Chen; Bridget F Koontz; Rebecca Paulus; Howard M Sandler
Journal:  J Clin Oncol       Date:  2016-04-04       Impact factor: 44.544

10.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.

Authors:  David Dearnaley; Isabel Syndikus; Helen Mossop; Vincent Khoo; Alison Birtle; David Bloomfield; John Graham; Peter Kirkbride; John Logue; Zafar Malik; Julian Money-Kyrle; Joe M O'Sullivan; Miguel Panades; Chris Parker; Helen Patterson; Christopher Scrase; John Staffurth; Andrew Stockdale; Jean Tremlett; Margaret Bidmead; Helen Mayles; Olivia Naismith; Chris South; Annie Gao; Clare Cruickshank; Shama Hassan; Julia Pugh; Clare Griffin; Emma Hall
Journal:  Lancet Oncol       Date:  2016-06-20       Impact factor: 41.316

View more
  1 in total

1.  Comparison of PKRP and TUVP in the treatment of high-risk BPH and analysis of postoperative influencing factors.

Authors:  Yao Song; Songqiang Pang; Gongtang Luo; Sen Li; Yaqiang He; Jinqiang Yang
Journal:  Front Surg       Date:  2022-08-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.